France set to become even tougher for medtech as elections loom: the details
This article was originally published in Clinica
Executive Summary
2012 is set to be a year full of important decisions impacting the French landscape, brought on by the climate of uncertainty resulting from recent healthcare product scandals. Alexandre Regniault, partner at the Paris office of law firm Simmons & Simmons, reflects on the current climate and the impact of the latest French regulatory measures